135 related articles for article (PubMed ID: 29358095)
1. Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells.
He L; Yang H; Zhou S; Zhu H; Mao H; Ma Z; Wu T; Kumar AK; Kathera C; Janardhan A; Pan F; Hu Z; Yang Y; Luo L; Guo Z
DNA Repair (Amst); 2018 Mar; 63():1-9. PubMed ID: 29358095
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA Flap Endonuclease 1 to Impede Breast Cancer Progression.
He L; Zhang Y; Sun H; Jiang F; Yang H; Wu H; Zhou T; Hu S; Kathera CS; Wang X; Chen H; Li H; Shen B; Zhu Y; Guo Z
EBioMedicine; 2016 Dec; 14():32-43. PubMed ID: 27852524
[TBL] [Abstract][Full Text] [Related]
3. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.
He L; Luo L; Zhu H; Yang H; Zhang Y; Wu H; Sun H; Jiang F; Kathera CS; Liu L; Zhuang Z; Chen H; Pan F; Hu Z; Zhang J; Guo Z
Mol Oncol; 2017 Jun; 11(6):640-654. PubMed ID: 28371273
[TBL] [Abstract][Full Text] [Related]
4. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
5. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.
Sreekanth CN; Bava SV; Sreekumar E; Anto RJ
Oncogene; 2011 Jul; 30(28):3139-52. PubMed ID: 21317920
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effect of a combination of paclitaxel and carboplatin with nobiletin from Citrus depressa on non-small-cell lung cancer cell lines.
Uesato S; Yamashita H; Maeda R; Hirata Y; Yamamoto M; Matsue S; Nagaoka Y; Shibano M; Taniguchi M; Baba K; Ju-ichi M
Planta Med; 2014 Apr; 80(6):452-7. PubMed ID: 24687742
[TBL] [Abstract][Full Text] [Related]
7. FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells.
Li JL; Wang JP; Chang H; Deng SM; Du JH; Wang XX; Hu HJ; Li DY; Xu XB; Guo WQ; Song YH; Guo Z; Sun MX; Wu YW; Liu SB
Cancer Med; 2019 Dec; 8(18):7774-7780. PubMed ID: 31670906
[TBL] [Abstract][Full Text] [Related]
8. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Qiu H; Li J; Liu Q; Tang M; Wang Y
Cell Cycle; 2018; 17(10):1235-1244. PubMed ID: 29886786
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2018 Sep; 503(4):2286-2292. PubMed ID: 29959920
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of FEN1 promotes DNA damage and enhances chemotherapeutic response in prostate cancer cells.
Wang Z; Yong C; Fu Y; Sun Y; Guo Z; Liu SB; Hu Z
Med Oncol; 2023 Jul; 40(8):242. PubMed ID: 37452976
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
12. Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin α2/β5/FAK signaling pathway.
Liu F; Tong D; Li H; Liu M; Li J; Wang Z; Cheng X
Oncotarget; 2016 Feb; 7(8):8896-907. PubMed ID: 26758421
[TBL] [Abstract][Full Text] [Related]
13. Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
Qiu F; Zhao X
J BUON; 2018; 23(1):117-123. PubMed ID: 29552770
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of isoprenylcysteine carboxylmethyltransferase sensitizes common chemotherapies in cervical cancer via Ras-dependent pathway.
Pan Q; Liu R; Banu H; Ma L; Li H
Biomed Pharmacother; 2018 Mar; 99():169-175. PubMed ID: 29331763
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
16. FEN1 inhibitor synergizes with low-dose camptothecin to induce increased cell killing via the mitochondria mediated apoptotic pathway.
Wu T; Zhu H; Zhang M; Sun Y; Yang Y; Gu L; Zhang J; Mu D; Wu C; Hu Z; Jiang L; Jia S; Zhang Y; He L; Pan FY; Guo Z
Gene Ther; 2022 Aug; 29(7-8):407-417. PubMed ID: 33414522
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
18. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.
Wang C; Wang R; Zhou K; Wang S; Wang J; Shi H; Dou Y; Yang D; Chang L; Shi X; Liu Y; Xu X; Zhang X; Ke Y; Liu H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):971-982. PubMed ID: 27620208
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.
Alami N; Page V; Yu Q; Jerome L; Paterson J; Shiry L; Leyland-Jones B
Growth Horm IGF Res; 2008 Dec; 18(6):487-96. PubMed ID: 18502161
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer.
Lu X; Liu R; Wang M; Kumar AK; Pan F; He L; Hu Z; Guo Z
Oncogene; 2020 Jan; 39(1):234-247. PubMed ID: 31471584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
